LSP4-2022 is a selective orthosteric mGlu4 receptor agonist with a target EC50 of 0.1 µM and blood-brain barrier permeability.LSP4-2022 activates mGlu4 via interactions with the conserved glutamate binding site and a variable Venus flytrap domain pocket, with no activity at group I and II mGlu receptors and reduced potency at mGlu6, mGlu7, and mGlu8 receptors.LSP4-2022 induces pro-depressant-like effects without altering locomotor activity, inhibits excitatory neurotransmission at parallel fiber-Purkinje cell synapses via presynaptic calcium transient reduction and paired-pulse facilitation increase, and reduces haloperidol-induced catalepsy in rats.LSP4-2022 can be used for the research of depression and parkinsons disease[1][2].
Molecular Weight:
347.26
Purity:
98.06
CAS Number:
[1413405-33-0]
Formula:
C13H18NO8P
Target:
mGluR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
